About the Company

CymaBay Therapeutics (NasdaqCM: CBAY) is a clinical stage biopharmaceutical company developing therapies for metabolic and orphan diseases. The Company’s lead product candidate is arhalofenate, an anti-flare and serum uric acid (sUA) lowering drug for the treatment of gout. Initial signs of efficacy have been shown in several Phase II trials. A pivotal Phase III program is expected to launch in the first half of 2016 pending partnership discussions. The Company’s is also developing MBX-8025 for the treatment of homozygous familial hypercholesterolemia (HoFH) and primary biliary cirrhosis (PBC). Results from a Phase II study in HoFH are expected in the fourth quarter of 2015 and CymaBay expects to initiate a Phase II study in PBC in the fourth quarter of 2015.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research